Filing Details

Accession Number:
0001062993-21-001012
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-08 18:37:38
Reporting Period:
2021-02-08
Accepted Time:
2021-02-08 18:37:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1785345 Landos Biopharma Inc. LABP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1249675 Ltd Fund Master Sciences Life Perceptive 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1757940 Perceptive Xontogeny Venture Fund, Lp 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1844296 Xontogeny, Llc 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-08 2,941,769 $0.00 2,941,769 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-02-08 2,941,769 $0.00 2,941,769 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-02-08 2,857,795 $0.00 5,799,564 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-02-08 2,857,795 $0.00 5,799,564 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-02-08 1,770,600 $0.00 1,770,600 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-02-08 1,250,000 $16.00 7,049,564 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2021-02-08 2,941,769 $0.00 2,941,769 $0.00
Common Stock Series A Preferred Stock Disposition 2021-02-08 2,941,769 $0.00 2,941,769 $0.00
Common Stock Series B Preferred Stock Disposition 2021-02-08 2,857,795 $0.00 2,857,795 $0.00
Common Stock Series B Preferred Stock Disposition 2021-02-08 2,857,795 $0.00 2,857,795 $0.00
Common Stock Series B Preferred Stock Disposition 2021-02-08 1,770,600 $0.00 1,770,600 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,090,924 Indirect See footnote
Footnotes
  1. Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.
  2. Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.
  3. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  4. The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  5. The securities are directly held by PX Venture (A), LLC. The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  6. The securities are directly held by Xontogeny, LLC ("Xontogeny"). C2 Ventures, LLC ("C2") is the manager of Perceptive XV Holdings, LLC ("Holdings"), the manager of Xontogeny. Joseph Edelman is the managing member of C2. Holdings, C2, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.